Less drug, stronger laser beam allow photodynamic therapy to reach deep chest cancer lesions, UB researchers find

April 07, 2000

RENO, NEV. -- Photodynamic therapy (PDT), one of the most promising new cancer treatments, may have much wider application than previously thought, new research by University at Buffalo researchers has shown.

Thomas S. Mang, Ph.D., UB clinical associate professor of oral and maxillofacial surgery, has found that by manipulating the amount of a light-sensitive drug and the intensity of the laser beam that activates it, he can successfully treat cancer cells deeply embedded in the chest wall without damaging surrounding normal tissue.

This low-dose PDT approach has resulted in complete healing in nearly 90 percent of 102 recurrent breast-cancer lesions.

Mang will present his findings here on April 8 at the annual meeting of the American Society for Laser Medicine and Surgery.

"These results offer further proof of the ability to lower drug concentrations and raise light intensity to successfully treat certain difficult tumors," said Mang, who conducted the study at the Photodynamic Therapy Center in Buffalo General Hospital of Kaleida Health, which he directs. "It allows broader application of this therapy in patients who can truly benefit from it."

PDT was developed at Roswell Park Cancer Institute, the site of UB's basic cancer research programs, and is thought to have significant potential for treating certain types of cancers. It has been approved to date for general use in treating non-small-cell lung cancer and obstructing esophageal tumors, and is being used on an experimental basis for several other tumor types.

The procedure exploits the propensity of cancer cells to absorb higher than normal concentrations of photosensitive drugs. When exposed to light via lasers, these drugs become toxic and destroy the malignant tissue. Since normal tissue surrounding tumors also absorbs a certain amount of the drug, the goal of researchers and clinicians is to find a drug-to-light ratio for each tumor type that will kill the most tumor cells while sparing the most normal tissue.

In the current study involving breast-cancer lesions that had formed on the chest wall, Mang lowered the standard 2.0 mg/kg dose of Photofrin, a photosensitive drug, to 0.8 mg/kg. "If we used the standard drug dose, we never would have been able to use a light dose that would reach deep enough to kill the tumor cells without destroying normal tissue," he said.

"By lowering the drug dose, the small amount of the drug in normal tissue bleaches out before it does any damage, and by delivering more light, we can reach deeper into tumors where the drug concentration is still high enough to kill cancer cells."

Mang and Ronald R. Allison, M.D., UB associate professor of clinical radiation oncology, treated nine patients with a total of 102 chest wall lesions. All the women had undergone surgery, full dose radiation and multiagent chemotherapy.

After receiving PDT, 89 percent of the lesions healed completely without scarring, Mang found. Of the remaining lesions, 8 percent became smaller. Three percent did not respond to the treatment.

"These results offer a glimpse of the parameters one might be able to use for treating whole fields of disease with little normal tissue damage," Mang said. "It gives us very good local control of disease."

University at Buffalo

Related Cancer Cells Articles from Brightsurf:

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.

Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.

Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.

Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.

Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.

Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.

Read More: Cancer Cells News and Cancer Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.